The numbers reported by the research team are striking. Among 49 patients with renal medullary carcinoma who underwent 18F-FDG PET/CT scans at MD Anderson between 2016 and 2025, the radiotracer detected lesions in 98 percent of cases, or 48 of the 49 patients. Even more consequential, in 65 percent of patients the tracer revealed additional cancer lesions that were not visualized on standard anatomical imaging such as computed tomography or magnetic resonance imaging. Those extra findings were not merely academic curiosities: in 21 percent of patients with active disease, the PET/CT results directly changed the clinical management plan, steering physicians away from treatments that would have been futile or harmful and toward strategies better matched to the true extent of disease.

Renal medullary carcinoma is a disease that demands precision from the very first scan. It predominantly affects adolescents and young adults, occurs more often in males, and is strongly associated with sickle cell trait and related hemoglobinopathies, conditions in which the oxygen-carrying environment of the renal medulla appears to create conditions favorable to tumor development. At the time of diagnosis, patients frequently already present with metastatic disease, and the median overall survival is approximately 14.5 months. Against that grim backdrop, every staging decision carries enormous weight. Surgery that might offer curative potential in localized disease becomes a source of suffering and delay when the cancer has in fact spread undetected, because high-morbidity operations postpone the systemic therapies that metastatic patients urgently need.

Simone Krebs, MD, MS, a nuclear medicine physician and scientist at MD Anderson and the study’s lead author, emphasized just how much rides on getting staging right in this disease. In renal medullary carcinoma, she noted, the value of accurate staging cannot be overstated, because upstaging a patient from localized to metastatic disease spares them from noncurative, high-morbidity surgeries that would only delay the initiation of essential systemic therapy. Identifying metastatic disease, she added, may also open opportunities for more effective therapies tailored to a patient’s actual disease burden. Her comments underscore a central tension in oncology: the difference between what imaging shows and what the cancer is actually doing can determine whether a patient receives the right treatment at the right time or loses precious months to the wrong one.

The biological basis for the study’s success lies in the way renal medullary carcinoma handles glucose. 18F-FDG is a glucose analog labeled with fluorine-18; it is taken up by cells through glucose transporters and then becomes metabolically trapped, allowing positron emission tomography to visualize tissues with high glycolytic activity. Many cancers are avid for FDG, but uptake varies considerably across kidney tumor subtypes, which has historically limited the tracer’s reputation in urologic oncology. Clear cell renal cell carcinoma, the most common kidney cancer, often shows variable FDG uptake, and some renal lesions are better characterized by other tracers or by dedicated CT protocols. Renal medullary carcinoma, however, demonstrates strong and consistent FDG uptake, distinguishing it from other kidney cancers and making it an unusually suitable target for FDG PET/CT imaging.

That metabolic avidity translated into practical diagnostic power even in patients who had already begun systemic treatment. The study found that 18F-FDG PET/CT remained highly effective after therapy had been initiated, an important point because treatment can alter tumor metabolism and degrade the performance of metabolic imaging in some cancers. In renal medullary carcinoma, the tracer continued to illuminate active disease, giving oncologists a reliable way to assess how patients were responding and whether residual lesions represented viable tumor. Quantitative PET/CT metrics were evaluated alongside visual interpretation, and the researchers systematically recorded every instance in which imaging findings altered treatment, providing a structured account of the scan’s real-world impact rather than anecdotal impressions.

The clinical consequences of the additional findings were often dramatic. In one illustrative case included in the published work, a patient demonstrated intense focal FDG uptake in nodal, hepatic, soft-tissue, and osseous metastases on maximum-intensity-projection imaging. Axial FDG PET and fused PET/CT images revealed focal intense uptake in the right iliac bone, a finding without a definite correlate on the dedicated CT image. That discrepancy, a metabolically active lesion invisible on anatomical imaging, led directly to changes in the patient’s clinical management. It is precisely this pattern, PET revealing disease that CT cannot confirm, that explains how the tracer upstaged so many patients and redirected so many treatment plans in the study cohort.

For patients, the implications of these findings are potentially life-altering. A young adult with renal medullary carcinoma who appears to have localized disease on a conventional CT scan might, in fact, harbor hepatic, nodal, or bone metastases that only PET/CT can reveal. Detecting those lesions before surgery could spare the patient a major operation that would never have been curative, while simultaneously accelerating access to systemic therapy, the treatment modality most likely to extend survival in metastatic disease. Conversely, for patients whose PET/CT confirms truly limited disease, the scan provides confidence that aggressive local treatment is justified. In both directions, the additional information changes decisions, and in a cancer with a median survival measured in months, better decisions translate directly into better use of the limited time available.

The study’s authors argue that the evidence now justifies a formal change in clinical practice. Their conclusion is that the findings may support the inclusion of 18F-FDG PET/CT in upcoming guidelines regarding renal medullary carcinoma, which would enable broader clinical use beyond specialized centers like MD Anderson. Guideline inclusion matters because renal medullary carcinoma is rare enough that many treating institutions will encounter only a handful of cases, and clinicians may default to conventional staging pathways unless professional society recommendations explicitly endorse metabolic imaging. Krebs and her colleagues contend that PET/CT provides clinically meaningful information beyond conventional imaging, helping doctors better assess the extent of disease and choose the most appropriate treatment strategy, and that on a larger scale the research supports wider adoption in routine patient care.

As molecular imaging continues to expand its role in oncology, the MD Anderson study offers a compelling case study in how an old, proven tool can find new purpose in an underserved disease. 18F-FDG has been a staple of nuclear medicine for decades, yet its value in kidney cancer has been considered limited and subtype-dependent. By rigorously documenting its performance specifically in renal medullary carcinoma, a population of predominantly young patients with few good options, the researchers have turned a routine radiotracer into a potential standard of care for one of oncology’s most aggressive diagnoses. With 98 percent detection, additional lesions found in nearly two-thirds of patients, and management changes in one in five, the case for FDG PET/CT in this disease is difficult to ignore, and the coming updates to clinical guidelines may soon make this powerful scan a routine part of the fight against renal medullary carcinoma.

Subject of Research: Use of 18F-FDG PET/CT imaging for staging and treatment planning in renal medullary carcinoma

Article Title: Proven radiotracer highly effective in detecting rare, aggressive kidney cancer

Article References: Proven radiotracer highly effective in detecting rare, aggressive kidney cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: renal medullary carcinoma, 18F-FDG PET/CT, kidney cancer, molecular imaging, metastatic disease, staging, nuclear medicine, radiotracer, MD Anderson Cancer Center, treatment planning, non-clear cell renal cell carcinoma, Journal of Nuclear Medicine

Renal cell carcinoma, representing the most common type of kidney cancer, manifests in various pathological forms, with clear cell renal cell carcinoma (ccRCC) being the most prevalent. In contrast, non-clear cell RCC (non-ccRCC) encompasses several less common variants, each with distinct biological behaviors and prognoses. While prior studies have extensively examined genetic and molecular determinants, the role of the tumor microenvironment, particularly the surrounding adipose tissue, has remained relatively underexplored until now.

The study employed a rigorous retrospective analysis of 297 RCC patients, stratifying them into two groups based on pathological diagnosis: 236 patients with ccRCC and 61 with non-ccRCC. Utilizing computed tomography (CT) imaging technology, the researchers quantified the perirenal fat area by measuring cross-sectional fat deposits at the renal vein level. This precise imaging-based assessment allowed for accurate correlations between fat volume and tumor characteristics to emerge from the data.

One of the critical findings was the identification of significant differences in perirenal fat areas between ccRCC and non-ccRCC groups. Patients diagnosed with ccRCC exhibited notably higher PFA measurements, contrasted with their non-ccRCC counterparts. Additionally, differences extended beyond fat area measurements to include clinical variables such as body weight and body mass index (BMI), both indicators of overall adiposity and metabolic health, which were found to differ significantly between the groups.

Importantly, the analysis did not merely stop at univariate observations. By deploying a multivariate logistic regression model, the investigators provided a nuanced understanding of how PFA independently correlates with RCC subtype likelihood, after adjusting for potential confounders. This approach reinforced the validity of their findings and suggested a more direct biological linkage between adipose tissue quantity and tumor phenotype, particularly in the context of clear cell carcinoma.

The spatial dimension of tumor location within the kidney emerged as another pivotal factor. Notably, when tumors were located outside the polar lines of the kidney (OPLK)—essentially the non-polar, midsection region of the organ—the association between PFA and ccRCC risk was accentuated. Quantitatively, each incremental increase of 1 cm² in perirenal fat area corresponded to a 5% heightened probability of the tumor being the clear cell subtype. This spatial dependency emphasizes that tumor microenvironmental factors, including regional fat deposition, may play different roles depending on anatomical tumor localization.

Further stratification still refined these insights. Focusing on patients within pathological stage T1 (denoting early-stage tumors confined to the kidney), the link between PFA and ccRCC became even more pronounced for tumors situated outside the polar lines. In such cases, every 1 cm² increase in PFA was associated with a 6% rise in ccRCC likelihood. Early-stage tumors represent a critical therapeutic window, so understanding factors that may predict pathological subtype at this stage holds clinical significance for personalized patient management.

These findings collectively hint at perirenal adipose tissue not just as a passive anatomical structure but potentially as an active player influencing RCC development and phenotypic expression. The metabolic and paracrine functions of adipose tissue could foster a microenvironment conducive to the pathogenesis or progression of clear cell carcinomas. Adipocytes are known to secrete a variety of bioactive molecules, including adipokines, cytokines, and growth factors, which can orchestrate inflammatory and signaling cascades relevant to tumor biology.

Intriguingly, the study also detected significant correlations with pathological staging, where certain stages demonstrated disparities in PFA between ccRCC and non-ccRCC groups. This suggests that perirenal fat’s influence might extend beyond mere tumor initiation to potentially affect tumor progression kinetics or aggressiveness. It underscores the need to consider fat tissue characteristics when evaluating tumor staging and designing intervention strategies.

The clinical implications are manifold. Firstly, leveraging PFA measurements through readily available CT imaging might serve as an adjunct predictive biomarker for RCC pathological type before invasive biopsy or surgery. Such non-invasive stratification could optimize surgical planning and patient counseling. Secondly, recognizing perirenal fat as a risk factor invites exploration into metabolic modulation or therapeutics targeting adipose tissue biology to indirectly influence tumor behavior.

In the broader context of cancer research, this study reinforces a growing paradigm where the tumor microenvironment, inclusive of adipose tissue, actively contributes to oncogenesis and tumor heterogeneity. It demands a multidisciplinary approach combining radiologic imaging, pathology, and molecular biology to unravel intricate tumor-host interactions. The novel observation of spatial dependency in the fat-tumor relationship opens avenues for further research to clarify mechanistic underpinnings.

Moreover, such data stimulate questions concerning lifestyle and systemic factors influencing perirenal fat accumulation, including obesity and metabolic syndrome, potentially linking systemic metabolic health with oncologic risks at organ-specific levels. This raises prospects for preventive strategies focusing on weight management and metabolic control as adjuncts to reduce RCC risk or improve prognosis.

Given the retrospective nature of the study, prospective cohort research and experimental models will prove essential to affirm causality and elucidate the molecular mechanisms by which perirenal adiposity modulates tumorigenesis. Biomolecular profiling of adipose tissue adjacent to tumors, alongside detailed phenotyping of ccRCC versus non-ccRCC cells, may unearth novel therapeutic targets embedded within the tumor microenvironment.

In summary, this comprehensive examination highlights a tangible association between perirenal fat area and clear cell renal carcinoma, particularly emphasizing the significance of tumor anatomical positioning within the kidney. These findings have the potential to reshape clinical perspectives on RCC risk assessment and pave the way for integrative approaches leveraging metabolic and anatomical biomarkers. As renal cancer remains a formidable clinical challenge globally, such insights carry promise for enhanced patient outcomes through more personalized care paradigms.

Subject of Research: The relationship between pathological types of renal cell carcinoma and perirenal fat area.

Article Title: The relationship between renal cell carcinoma pathological types and perirenal fat area.

Article References:
Leng, X., Zhou, C., Wu, J. et al. The relationship between renal cell carcinoma pathological types and perirenal fat area. BMC Cancer 25, 841 (2025). https://doi.org/10.1186/s12885-025-14164-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14164-2